FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

**OMB APPROVAL** OMB Number: Estimated average burden

0.5

hours per response:

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				0	r Section	on 30(n) (	of the	Investment C	company Act	of 1940							
1. Name and Address of Reporting Person <sup>*</sup> Merrigan Paul J						2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. [ CPRX ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify				
(Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 1250					3. Date of Earliest Transaction (Month/Day/Year) 12/30/2015							X Officer (give title Officer below)  Chief Commercial Officer					
(Street) CORAL GABLES	s FI	33134	4.	If Ame	ndment, I	Date	te of Original Filed (Month/Day/Year)				6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting						
(City) (St		tate)	(Zip)		Person												
		Tab	le I - Non-De	rivativ	e Se	curities	s Ac	quired, D	isposed (	of, or Be	neficial	ly Owned					
1. Title of Security (Instr. 3)			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on Dispose	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		Beneficia Owned F	es F ally (I Following (I	Ownership orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	tion(s)		(Instr. 4)		
		-	Table II - Der (e.g					uired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Trans Code ) 8)				6. Date Exer Expiration D (Month/Day/	ate	e and 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Options to purchase common stock	\$2.53	12/30/2015		A		50,000		12/30/2016	12/30/2022	Common Stock	50,000	\$0	200,000	D			
Options to purchase common stock	\$2.53	12/30/2015		A		50,000		12/30/2017	12/30/2022	Common Stock	50,000	\$0	250,000	D			
Options to purchase common	\$2.53	12/30/2015		A		50,000		12/30/2018	12/30/2022	Common Stock	50,000	\$0	300,000	D			

**Explanation of Responses:** 

/s/ Paul J. Merrigan

01/04/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).